Innovation is the driving force behind Crucell’s future growth supported by a strong research and development (R&D) pipeline. Our scientists focus on the discovery and development of much-needed solutions for major threats to human health—particularly vaccines and antibodies for the prevention and treatment of infectious diseases. This has resulted in a broad pipeline of investigational products with the potential to revolutionize the fight against diseases such as influenza, rabies, malaria and tuberculosis.
In this section you can read more about the discovery and development of next-generation medical products facilitated by our range of innovative technologies.
Our current R&D pipeline includes the following product areas:
Recombinant antibodies: Recombinant antibodies, such as blood factors, can be produced efficiently and safely on the PER.C6® human cell line.
Learn more about Crucell’s development programs